Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Odhalení: Studie fáze 3 ION582 v Angelmanově syndromu

12. listopadu 2026 aktualizováno: Ionis Pharmaceuticals, Inc.

Studie účinnosti a bezpečnosti ION582 z fáze 3 u dětí a dospělých se syndromem Angelmana

The purpose of this study is to evaluate the efficacy and safety of obudanersen in children and adults with Angelman syndrome caused by a deletion or mutation of the UBE3A gene.

Přehled studie

Postavení

Aktivní, ne nábor

Detailní popis

This is a Phase 3, randomized, double-blind, placebo-controlled study in people with Angelman syndrome. The study will consist of 4 periods: a screening period of up to 28 days, an approximate 60-week double blind, placebo-controlled treatment period, followed by an approximate 25-month Long-Term Extension (LTE) treatment period, and an approximate 8-month Post-LTE follow-up period. The study will be comprised of 2 cohorts. Cohort 1 will include pediatric participants, aged 2 to less than (<)18 years old and serve as the population for evaluation of primary and secondary outcome measures; Cohort 2 will include adult participants, aged 18 to ≤50 years old. Participants will be randomized 1:1 to 80 mg obudanersen or placebo during the double-blind placebo-controlled treatment period. Participants from both cohorts completing the placebo-controlled treatment period will be eligible to transition into the LTE Treatment Period wherein all trial participants will receive obudanersen. Participant, Caregiver, Investigator and Sponsor will remain blinded to the obudanersen dose administered to participants during the LTE.

The study initiated in 2024 with three dosing groups (40 mg obudanersen, 80 mg obudanersen, and placebo). Following additional review of data from the ongoing Phase 1/2 trial of obudanersen (HALOS), REVEAL was amended in December 2025 to its current form as a two-arm study: 80 mg obudanersen and placebo. Following the amendment, participants who were randomized to receive 40 mg obudanersen will be transitioned to receive 80 mg obudanersen.

Typ studie

Intervenční

Zápis (Aktuální)

156

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

      • Nedlands, Austrálie, 6009
        • Perth Children's Hospital
      • Randwick, Austrálie, 2031
        • Sydney Children's Hospital
    • Queensland
      • South Brisbane, Queensland, Austrálie, 4101
        • Queensland Children's Hospital
      • Milan, Itálie, 20133
        • Fondazione IRCCS Istituto Neurologico Carlo Besta
      • Pisa, Itálie, 56126
        • Azienda Ospedaliero Universitaria Pisana
      • Roma, Itálie, 00165
        • Ospedale Pediatrico Bambino Gesù
      • Ramat Gan, Izrael, 5265601
        • Sheba Medical Center
    • Osaka
      • Izumi, Osaka, Japonsko, 594-1101
        • Osaka Women's and Children's Hospital
    • Tokyo
      • Kodaira, Tokyo, Japonsko, 187-8551
        • National Center of Neurology and Psychiatry
      • Seoul, Jižní Korea, 03080
        • Seoul National University Hospital
      • Seoul, Jižní Korea, 06351
        • Samsung Medical Center
      • Edmonton, Kanada, T6G 2B7
        • University of Alberta Hospital
      • Vancouver, Kanada, V6H 3V4
        • British Columbia Children's Hospital
    • Ontario
      • London, Ontario, Kanada, N6A 5W9
        • London Health Science Centre - Children's Hospital
    • Quebec
      • Montreal, Quebec, Kanada, H4A 3J1
        • McGill University Health Centre
      • München, Německo, 81377
        • Klinikum der Ludwig-Maximilians-Universitaet Muenchen
      • Gdansk, Polsko, 80-952
        • Uniwersyteckie Centrum Kliniczne
      • Singapore, Singapur, 229899
        • KK Women's and Children's Hospital
      • London, Spojené království, WC1N 3JH
        • Great Ormond Street Hospital for Children - NHS Foundation Trust
      • Oxford, Spojené království, OX3 9DU
        • John Radcliffe Hospital
    • California
      • Los Angeles, California, Spojené státy, 90048
        • Cedars-Sinai Medical Center
      • Los Angeles, California, Spojené státy, 90095
        • UCLA Clinical & Translational Research Center (CTRC)
      • San Diego, California, Spojené státy, 92123
        • Rady Children's Hospital
    • Colorado
      • Aurora, Colorado, Spojené státy, 80045
        • Colorado Children's Hospital Research Institute
    • District of Columbia
      • Washington D.C., District of Columbia, Spojené státy, 20011
        • Children's National Hospital
    • Florida
      • Miami, Florida, Spojené státy, 33155
        • Nicklaus Children's Hospital
    • Georgia
      • Atlanta, Georgia, Spojené státy, 30329
        • Children's Healthcare of Atlanta
    • Illinois
      • Chicago, Illinois, Spojené státy, 60612
        • Rush University Medical Center
    • Massachusetts
      • Boston, Massachusetts, Spojené státy, 02115
        • Boston Children's Hospital
    • Missouri
      • Kansas City, Missouri, Spojené státy, 64108
        • Children's Mercy
    • New York
      • New York, New York, Spojené státy, 10032
        • Columbia University Irving Medical Center
      • New York, New York, Spojené státy, 10029
        • Ichan School of Medicine at Mount Sinai
    • North Carolina
      • Carrboro, North Carolina, Spojené státy, 27510
        • University of North Carolina at Chapel Hill School of Medicine
    • Ohio
      • Cincinnati, Ohio, Spojené státy, 45229
        • Cincinnati Children's Hospital
      • Columbus, Ohio, Spojené státy, 43205
        • Nationwide Children's Hospital
    • Pennsylvania
      • Philadelphia, Pennsylvania, Spojené státy, 19104
        • Children's Hospital of Philadelphia
    • Tennessee
      • Nashville, Tennessee, Spojené státy, 37232
        • Vanderbilt Clinical Research Center
    • Texas
      • Houston, Texas, Spojené státy, 77030
        • Texas Children's Hospital
      • Barcelona, Španělsko, 08950
        • Hospital Sant Joan de Deu
      • Sabadell, Španělsko, 08208
        • Corporacio Sanitaria Parc Tauli - Hospital de Sabadell

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

2 roky až 50 let (Dítě, Dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Key Inclusion Criteria:

  1. The participants caregiver(s)/ legally authorized representative must have given written informed consent and any authorizations required by local law and be able to comply with all study requirements.
  2. Medically stable and can undergo sedation and/or general anesthesia without intubation.
  3. Male or female between 2 and lesser than or equal to (≤)50 years of age, depending on specific cohort, at the time of the in-clinic Screening visit.
  4. Participant has a clinical diagnosis of Angelman syndrome (AS) with molecular confirmation of either Ubiquitin-protein ligase E3A (UBE3A) deletion or UBE3A mutation.
  5. Currently receiving stable doses of concomitant medications typically prescribed for AS, such as anti-epileptic medication, behavioral management medications, sleep medications, gabapentin, cannabidiol, and special diets, supplements, or nutritional support for at least 8 weeks prior to the Baseline visit.
  6. Legally authorized representative/caregiver(s) agree(s) not to post any of the participant's personal medical data or information related to the study on any website or social media site (e.g., Facebook, Instagram, X (formerly Twitter), YouTube, TikTok, etc.) from the time of enrollment until they are notified that the study is completed.

Key Exclusion Criteria:

  1. Must not have any clinically significant abnormalities in medical history (e.g., major surgery within 3 months of screening), or on physical examination for which treatment with an antisense oligonucleotide (ASO) would be contraindicated or which, in the opinion of the Principal Investigator (PI), could confound the results of this study.
  2. Known brain or spinal disease that would interfere with the lumbar puncture (LP) procedure, cerebrospinal fluid (CSF) circulation, or presence of other factors would affect the safety of the LP procedure.
  3. Must not have any other conditions, which, in the opinion of the Investigator, would make the participant unsuitable for inclusion or could interfere with the participant participating in or completing the study.
  4. Must not have any laboratory abnormalities or any other clinically significant abnormalities that would, as assessed by the Investigator, at screening or Baseline, render a participant unsuitable for inclusion.
  5. Previous treatment with an oligonucleotide (including small interfering ribonucleic acid (RNA) [siRNA], ASOs) gene therapy or gene editing. This exclusion criterion does not apply to approved nucleic acid-based vaccines, including mRNA vaccines, which are allowed.
  6. Has molecular confirmation of AS due to paternal uniparental disomy, imprinting center defect, or mosaic findings.

Other inclusion/exclusion criteria may apply.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Čtyřnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Cohort 1 obudanersen 80 mg

Participants (aged 2 to <18 years old) will be administered obudanersen 80 mg via intrathecal (IT) injection every 12 weeks during the double blind and LTE treatment periods.

obudanersen will be administered by IT injection.

Ostatní jména:
  • ION582
Komparátor placeba: Cohort 1 Placebo

Participants (aged 2 to <18 years old) will be administered obudanersen matching placebo via IT injection every 12 weeks during the double-blind treatment period and then administered obudanersen 40 mg or 80 mg every 12 weeks during the LTE treatment period.

obudanersen matching placebo will be administered by IT injection.

Experimentální: Cohort 2 obudanersen 80 mg

Participants (aged 18 to ≤50 years old) will be administered obudanersen 80 mg via IT injection every 12 weeks during the double blind and LTE treatment periods.

obudanersen will be administered by IT injection.

Ostatní jména:
  • ION582
Komparátor placeba: Cohort 2 Placebo

Participants (aged 18 to ≤50 years old) will be administered obudanersen matching placebo via IT injection every 12 weeks during the double-blind treatment period and then randomized to obudanersen 40 mg or 80 mg every 12 weeks during the LTE treatment period.

obudanersen matching placebo will be administered by IT injection.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in Performance on the Expressive Communication Subdomain Raw Score of the Bayley Scales for Infant and Toddler Development-4 (Bayley-4) Without Caregiver Input in Cohort 1
Časové okno: Baseline and Week 52

The Bayley-4 is a performance-based assessment of developmental functioning across communication, cognition, and motor skills. The expressive communication subdomain of communication measures preverbal and verbal communication. The total raw score reflects the sum of all the item scores within the expressive communication subdomain, with higher scores reflecting greater expressive communication ability.

Baseline and Week 52

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Procento účastníků s nepříznivými účinky (TEAE) a vážnými nežádoucími účinky (SAES)
Časové okno: Až do týdne 52
Až do týdne 52
Změna vitálních funkcí a výsledků klinické laboratoře
Časové okno: Základní linie a týden 52
Základní linie a týden 52
Change in Bayley Scales for Infant and Toddler Development-4 (Bayley-4): Cognition Subdomain Raw Score Without Caregiver Input
Časové okno: Baseline and Week 52

The Bayley-4 is a performance-based assessment of developmental functioning across communication, cognition, and motor skills. The cognitive subdomain measures learning, memory and concept formation. The total raw score reflects the sum of all the item scores within the expressive communication subdomain, with higher scores reflecting greater cognitive ability.

Baseline and Week 52
Change in Symptoms of Angelman Syndrome -Clinician Global Impression of Change (SAS-CGI-C): Overall AS
Časové okno: Baseline and Week 52

The SAS-CGI-C for Overall AS is a disease-specific clinician-reported outcome assessment measure for Angelman syndrome. The clinicians rate their overall impression of the change of the participant's Angelman syndrome symptoms utilizing a 7-point scale, ranging from "very much improved" (1) to "very much worse" (7).

Baseline and Week 52
Change in Vineland Adaptive Behavior Scale-3 (Vineland-3): Receptive Communication Subdomain Raw Score
Časové okno: Baseline and Week 52

The Vineland-3 assesses adaptive behaviors across 4 domains via a semi-structured interview between a trained clinician and the caregiver of the participant with AS. The receptive communication subdomain of communication measures the participant's ability to attend, understand, and respond appropriately to information from others. The total raw score reflects the sum of all the item scores within the receptive communication subdomain, with higher scores reflecting greater receptive communication ability.

Baseline and Week 52
Change in Vineland Adaptive Behavior Scale-3 (Vineland-3): Daily Living Skills, Personal Subdomain Raw Score
Časové okno: Baseline and Week 52

The Vineland-3 assesses adaptive behaviors across 4 domains via a semi-structured interview between a trained clinician and the caregiver of the participant with AS. The Personal subdomain of the Daily Living Skills domain measures the participant's self-sufficiency in such areas as eating, dressing, washing, hygiene, and health care. The total raw score reflects the sum of all the item scores within the Personal subdomain, with higher scores reflecting greater ability.

Baseline and Week 52
Change in Symptoms of Angelman Syndrome - Clinician Global Impression of Change (SAS-CGI-C): Sleep Problems
Časové okno: Baseline and Week 52

The SAS-CGI-C for Sleep Problems is a disease-specific clinician-reported outcome assessment measure for Angelman syndrome. The clinicians rate their overall impression of the change in the participant's sleep problems utilizing a 7-point scale, ranging from "very much improved" (1) to "very much worse" (7).

Baseline and Week 52
Change in Bayley Scales for Infant and Toddler Development-4 (Bayley-4): Fine Motor Subdomain Raw Score Without Caregiver Input
Časové okno: Baseline to Week 52

The Bayley-4 is a performance-based assessment of developmental functioning across communication, cognition, and motor skills. The Fine Motor subdomain of communication measures motor abilities such as reaching, object manipulation, and grasping. The total raw score reflects the sum of all the item scores within the fine motor subdomain, with higher scores reflecting greater fine motor ability.

Baseline to Week 52
Change in Observer-Reported Communication Ability (ORCA): Overall Emerging T Score
Časové okno: Baseline and Week 52

The ORCA measure assesses, from the caregiver's perspective, the communication ability of individuals with neurodevelopmental disorders, like Angelman syndrome. This questionnaire assesses expressive, receptive, and pragmatic communication. The ORCA measure produces a single score that is an estimate of an individual's overall level of communication ability, with higher T-scores reflecting greater communication ability.

Baseline and Week 52

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

10. června 2025

Primární dokončení (Odhadovaný)

1. srpna 2027

Dokončení studie (Odhadovaný)

1. dubna 2030

Termíny zápisu do studia

První předloženo

22. března 2025

První předloženo, které splnilo kritéria kontroly kvality

31. března 2025

První zveřejněno (Aktuální)

6. dubna 2025

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

16. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

12. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

Ionis may share anonymized individual participant data, aggregated clinical data, and other types of data that support the results in this study. Data requests from qualified researchers will be considered once all three of the following criteria are met: (1) 12 months from marketing approval of the study drug in both the United States and European Union; (2) 18 months from conclusion of the study; and (3) 6 months from publication of study article. Access would be via a secure environment and is contingent upon approval of a research proposal and entry into an appropriate data use agreement. Requests to access data can be submitted via the website https://vivli.org/ourmember/ionis/.

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit